ARGX Stock Analysis: Buy, Sell, or Hold?
ARGX - argenx SE American Depositary Shares
$876.25
-1.37 (-0.16%)
▼
5d:
-4.42%
30d:
+1.63%
90d:
+9.58%
BUY
HIGH Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Jul 30, 2026
15d
Get Alerted When ARGX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ARGX shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: ARGX shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$1567.53
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$973.31
10.0% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ARGX is currently trading at $876.25, which is considered slightly low relative to its 30-day fair value range of $871.79 to $915.04. The stock's valuation (Forward PE: 27.2) is in line with its historical norms (28.1). Remarkably, the market is currently pricing in an annual earnings decline of 1.1% over the next few years. This pessimistic expectation contrasts with the company's recent 114.0% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ARGX is in a strong uptrend. The price is currently testing key support at $855.78. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $1052.63 (+20.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ARGX is in a strong uptrend. The price is currently testing key support at $855.78. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $1052.63 (+20.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$871.79 -
$915.04
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 20.1% below Wall St target ($1052.63)
Trading Range Analysis
30-Day Trading Range
$871.79 -
$915.04
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$855.78
Resistance Level
$953.58
Current Trend
Strong Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
27.21
Wall Street Target
$1052.63
(+20.1%)
Revenue Growth (YoY)
62.6%
Earnings Growth (YoY)
114.0%
Profit Margin
31.4%
Valuation Discount vs History
-1.1% cheaper
PE vs Historical
27.2 vs 28.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.1%
(market-implied from PE analysis)
1-Year Target
$866.61
(-1%)
2-Year Target
$857.08
(-2%)
3-Year Target
$847.65
(-3%)
3-Yr Target (if PE normalizes)
(PE: 27→28)
$875.24
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 27.2, Growth: 42.6%)
$2541.10
(+190%)
Base:
(SPY PE: 21.8, Growth: 42.6%)
$2033.68
(+132%)
Bear:
(PE: 18.5, Growth: 42.6%)
$1728.63
(+97%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (39x PE), but valuation improves significantly next year (27x PE) as earnings recover.
Trailing PE: 38.92 | Current EPS (TTM): $22.55
Bull Case
$1378.43
(+57%)
Analyst growth 42.8%, PE expands to 42.8
Base Case
$1253.11
(+43%)
Market implied 42.8%, PE stable at 38.9
Bear Case
$596.78
(-32%)
Severe decline -20.0%, PE contracts to 33.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 27.2 to 28.1
Stabilization Target:
$904.77
(+3.3%)
PE Expansion Potential:
+3.3%
Share & Embed Analysis
Last updated: July 14, 2026 12:26 AM ET
Data refreshes hourly during market hours. Next update: 1:26 AM
Data refreshes hourly during market hours. Next update: 1:26 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ARGX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 66 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 64 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 50 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$124 | 61 BUY |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$297 | 61 BUY |
